Impact of Data Base Structure in a Successful In Vitro-In Vivo Correlation for Pharmaceutical Products

被引:5
作者
Roudier, B. [1 ,2 ]
Davit, B. [3 ]
Schuetz, H. [4 ]
Cardot, J-M. [2 ]
机构
[1] ESIEE Cites Descartes, F-93162 Paris, France
[2] Auvergne Univ, Dept Biopharmaceut, EA4678, UFR Pharm, Clermont Ferrand, France
[3] Merck Res Labs, Biopharmaceut, Whitehouse Stn, NJ 08889 USA
[4] BEBAC, A-1070 Vienna, Austria
关键词
CPP; CQA; IVIVC; object-oriented database; QbD; OBJECT-ORIENTED DATABASES; MODEL;
D O I
10.1208/s12248-014-9680-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The in vitro-in vivo correlation (IVIVC) (Food and Drug Administration 1997) aims to predict performances in vivo of a pharmaceutical formulation based on its in vitro characteristics. It is a complex process that (i) incorporates in a gradual and incremental way a large amount of information and (ii) requires information from different properties (formulation, analytical, clinical) and associated dedicated treatments (statistics, modeling, simulation). These results in many studies that are initiated and integrated into the specifications (quality target product profile, QTPP). This latter defines the appropriate experimental designs (quality by design, QbD) (Food and Drug Administration 2011, 2012) whose main objectives are determination (i) of key factors of development and manufacturing (critical process parameters, CPPs) and (ii) of critical points of physicochemical nature relating to active ingredients (API) and critical quality attribute (CQA) which may have implications in terms of efficiency, safety, and inoffensiveness for the patient, due to their non-inclusion. These processes generate a very large amount of data that is necessary to structure. In this context, the storage of information in a database (DB) and the management of this database (database management system, DBMS) become an important issue for the management of projects and IVIVC and more generally for development of new pharmaceutical forms. This article describes the implementation of a prototype object-oriented database (OODB) considered as a tool, which is helpful for decision taking, responding in a structured and consistent way to the issues of project management of IVIVC (including bioequivalence and bioavailability) (Food and Drug Administration 2003) necessary for the implementation of QTPP.
引用
收藏
页码:24 / 34
页数:11
相关论文
共 17 条
[1]  
[Anonymous], 1997, GUID IND EXT REL OR
[2]  
[Anonymous], 2003, GUID IND BIOAV BIOEQ
[3]   Support for modeling relationships in object-oriented databases [J].
Beraha, S ;
Su, JW .
DATA & KNOWLEDGE ENGINEERING, 1999, 29 (03) :227-257
[4]   PKC, a new pharmacokinetic software using SAS(R) [J].
Cardot, JM ;
Jaouen, A ;
Godbillon, J .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1997, 43 (02) :197-199
[5]  
Devane JG, 1997, VIVO IN VITRO CORREL, V423, P241
[6]  
Dunne A., 2007, DRUGS PHARM SCI, V165, P47
[7]  
Emani J, 2009, J PHARM PHARM SCI, V9, P169
[8]  
Food and Drug Administration, 2011, QUAL DES ANDAS EX MO
[9]  
Food and drug administration, 2012, QUAL DES ANDAS EX IM
[10]  
Garardin G, 2003, LES BASES DE DONNEES